Is there a Biosimilar Communications Breakdown?
Biosimilars are still struggling to gain maximum traction in the marketplace….. and a recent survey says that communications are at the heart of the problem.
Biosimilars are still struggling to gain maximum traction in the marketplace….. and a recent survey says that communications are at the heart of the problem.
June 28, 2022Winter Garden, FLThe FDA recently approved a new sub-cutaneous, specialty therapy, Amvuttra (vutrisiran) from Alnylam Pharmaceuticals, for the treatment of the polyneuropathy of
The word on the street is that CVS has acquired US Bioservices from AmerisourceBergen….. and it seems that CVS is treating it as a closely
The topic of the article below did not get much coverage in the media….. and that is unfortunate….. the issue should be important to all
Specialty pharmacies have, presumably, been preparing to implement new workflows to accommodate the anticipated January launch of new CMS regulations related to copay accumulator transactions.
The FDA recently approved a new form of therapy for ALS. Normally, a new form is not big news, but, for this therapy, it may
The FDA recently approved the fourth pegfilgrastim biosimilar referencing Neulasta, Fylnetra (pegfilgrastim-pbbk) from Amneal Pharmaceuticals. Fylnetra is a leukocyte growth factor indicated to decrease the
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
Now here’s something ya don’t see every day!A drug approved within the last year being yanked from the market. This week, the FDA pulled approval
Back in February we sent a report detailing an innovative network approach to alternate site / home infusion and it seems to be a topic